Fuxiang Pharmaceutical: Announcement on Obtaining a U.S. Invention Patent Certificate
Securities code: 300497 Securities abbreviation: Fuxiang Pharmaceutical Announcement number: 2026-026
Jiangxi Fuxiang Pharmaceutical Co., Ltd.
Announcement on Obtaining a U.S. Invention Patent Certificate
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Recently, Jiangxi Fuxiang Biotechnology Co., Ltd., a subsidiary of Jiangxi Fuxiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), obtained an invention patent certificate issued by the United States Patent and Trademark Office. The details are as follows:
1. Basic information on invention patent certificate
(1) Title of the invention: Application of Fusarium brevis in the production of mycelium protein
U.S. Patent Number: US12,529,027 B2
Application number: 18/850,239
Authorization date: January 20, 2026
Patentee: Jiangxi Fuxiang Biotechnology Co., Ltd.
Inventors: Bao Jianhua, Tu Yadong, Li Jialu, Li Huiyue, Chen Yinghui
Address: South side of the power plant, Changjiang District, Jingdezhen City, Jiangxi Province, 333000
2. The impact of obtaining an invention patent certificate on the company
In recent years, based on the advantageous resources accumulated in the pharmaceutical industry over the years, the company has expanded its synthetic biology microbial protein business and has become the first domestic enterprise to achieve kiloton industrialization of filamentous fungal protein. The company has a new production strain with completely independent intellectual property rights - Fusarium brachypodium. It has been identified by the China Light Industry Federation Appraisal Committee that the overall technology of the "Key Technology for Microbial Protein Production by Fusarium Brachypodium Fermentation and Industrial Application" project has reached the international advanced level, and the technology for breeding microbial strains for high-quality protein production has reached the international leading level.
Previously, this technology has obtained Chinese invention patents and Korean invention patents. This time, the invention patent issued by the United States Patent and Trademark Office for "Application of Fusarium brevis in the production of mycelium protein" is one of the important developments in the company's international strategic layout of microbial protein business, marking that the company's core technology has been officially recognized by the United States. This patent will provide a solid technical barrier for the company's novel protein products to enter the US market and significantly enhance the core competitiveness of this business segment. This breakthrough is an important step for the company to achieve globalization. It has laid an intellectual property foundation for subsequent expansion into more countries and regions. It is expected to occupy a favorable position in the increasingly fierce international competition and accelerate the overseas expansion of the microbial protein business.
At present, this patented technology has been applied to the company's existing production lines and is not expected to have a significant impact on recent operating results. However, it has positive and far-reaching strategic significance for the company's long-term business development, global market development and the establishment of sustainable competitive advantages.
3. Documents for reference
"U.S. Invention Patent Certificate" (Patent No.: US12,529,027 B2)
Announcement is hereby made.
Board of Directors of Jiangxi Fuxiang Pharmaceutical Co., Ltd.
March 26, 2026